Zinzani P L, Baccini C, Zaccaria A, Visani G, Buzzi M, Morelli A, Molinari A L, Salvucci M, Bendandi M, Rubboli D, Gherlinzoni F, Zanchini R, Tura S
Institute of Hematology Seràgnoli, University of Bologna, Italy.
Eur J Haematol. 1996 Nov;57(5):335-40. doi: 10.1111/j.1600-0609.1996.tb01390.x.
In the last few years the research for new biological features in low-grade non-Hodgkin's lymphoma has provided important results. Several biological parameters are under evaluation and, in particular, cytokines and soluble receptors levels are showing their importance as prognostic parameters. In the present study, serum levels of tumor necrosis factor alpha (TNF-alpha) and soluble CD23 (sCD23) were measured at the time of diagnosis and after induction polychemotherapy in 40 patients with newly diagnosed low-grade non-Hodgkin's lymphoma (LG-NHL). The treatments were CIOP (cyclophosphamide, idarubicin, vincristine, prednisone) regimen for 28 patients and FMP (fludarabine, mitoxantrone, prednisone) scheme for 12 patients. Pretreatment levels of TNF-alpha were highly elevated in patiets with LG-NHL compared with healthy controls (p = 0.005) and were significantly correlated with the Ann Arbor stage (p = 0.001). sCD23 was detected in 35 patients at diagnosis and were markedly increased in LG-NHL patients when compared to healthy controls (p = 0.005); patients with advanced stage presented higher values than those with early stage disease (p = 0.002). All the complete responders (20/40, 50%) showed a decrease of TNF-alpha and sCD23 levels. By contrast, the combination of high levels of TNF-alpha and sCD23 correspond to a group of non-responders. Our results suggest that TNF-alpha and sCD23 are specific prognostic parameters for LG-NHL, and that they could be used as tumor markers within a potential biological prognostic index.
在过去几年中，对低度非霍奇金淋巴瘤新生物学特征的研究取得了重要成果。多个生物学参数正在评估中，特别是细胞因子和可溶性受体水平作为预后参数的重要性日益显现。在本研究中，对40例新诊断的低度非霍奇金淋巴瘤（LG-NHL）患者在诊断时及诱导多药化疗后测定了血清肿瘤坏死因子α（TNF-α）和可溶性CD23（sCD23）水平。28例患者采用CIOP（环磷酰胺、伊达比星、长春新碱、泼尼松）方案治疗，12例患者采用FMP（氟达拉滨、米托蒽醌、泼尼松）方案治疗。与健康对照相比，LG-NHL患者的TNF-α预处理水平显著升高（p = 0.005），且与Ann Arbor分期显著相关（p = 0.001）。35例患者在诊断时检测到sCD23，与健康对照相比，LG-NHL患者的sCD23明显升高（p = 0.005）；晚期患者的值高于早期疾病患者（p = 0.002）。所有完全缓解者（20/40，50%）的TNF-α和sCD23水平均下降。相比之下，高水平的TNF-α和sCD23组合对应一组无反应者。我们的结果表明，TNF-α和sCD23是LG-NHL的特异性预后参数，它们可作为潜在生物学预后指标中的肿瘤标志物。
